toripalimab
Sign in to saveAlso known as Loqtorzi
Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.
Clinical Trials
442 registered- PHASE3RECRUITING9MW2821 in Combination With Toripalimab vs Standard Chemotherapy in Locally Advanced or Metastatic Urothelial CancerMabwell (Shanghai) Bioscience Co., Ltd. · NCT06592326
- PHASE2NOT_YET_RECRUITINGPDT For Induction Therapy For Head And Neck CancerMassachusetts General Hospital · NCT07214987
- PHASE1ENROLLING_BY_INVITATIONJS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib StudyXiangya Hospital of Central South University · NCT06882876
- PHASE2UNKNOWNThe Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III MelanomaYong Chen · NCT05827770
- NAUNKNOWNToripalimab Based Induction Chemotherapy Followed by De-escalation Protocols in HPV-related OPSCCFudan University · NCT04867330
- PHASE2ACTIVE_NOT_RECRUITINGToripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell LymphomaCancer Institute and Hospital, Chinese Academy of Medical Sciences · NCT06492629
~3 min read
Article
6 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- References
- External links
Toripalimab, sold under the brand name Loqtorzi, is a monoclonal antibody used for the treatment of melanoma and nasopharyngeal carcinoma. Toripalimab is a recombinant humanized programmed cell death protein 1 (PD-1) monoclonal antibody that acts as a checkpoint inhibitor.
In 2018, toripalimab was approved in China for the treatment of unresectable or metastatic melanoma that has failed previous systemic therapy. In October 2023, the US Food and Drug Administration (FDA) approved toripalimab for the first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma when used with cisplatin and gemcitabine.